Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of 1,2,3,4,6-five-O-gallnut acyl radical-b-D-glucose

A technology based on galloyl and glucose, which is applied in the field of preparation of drugs against herpes simplex type 1 virus, which can solve the problems of inability to clear the virus, and achieve the effects of rapid recovery, low drug toxicity, and alleviating symptoms

Inactive Publication Date: 2009-06-24
JINAN UNIVERSITY
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Herpes simplex virus infection is widespread in the population. Most of the initial primary infection forms a recessive infection without clinical symptoms. After infection, neutralizing antibodies are produced. Antibody tests are positive in 60%-90% of the population, but the virus cannot be cleared

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of 1,2,3,4,6-five-O-gallnut acyl radical-b-D-glucose
  • Use of 1,2,3,4,6-five-O-gallnut acyl radical-b-D-glucose
  • Use of 1,2,3,4,6-five-O-gallnut acyl radical-b-D-glucose

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Drug dilution: Dilute the drug storage solution with MEM maintenance solution, and the doubling dilution is 20μg / ml, 10μg / ml, 5μg / ml, 2.5μg / ml, 1.25μg / ml.

[0026] Positive control drug ACV dilution: Dissolve 10 mg ACV sample in 100 μl deionized water to prepare drug mother solution, store it at 4°C for a long time, dilute it with MEM maintenance solution when used, and dilute it to 20 μg / ml, 10 μg / ml, 5 μg / ml, 2.5 μg / ml ml, 1.25 μg / ml.

[0027] 20μg / ml, 10μg / ml, 5μg / ml, 2.5μg / ml, 1.25μg / ml of 1,2,3,4,6-penta-O-galloyl-b-D-glucose maintenance solution and 20μg / ml , 10 μg / ml, 5 μg / ml, 2.5 μg / ml, 1.25 μg / ml ACV maintenance solution was added to the wells of monolayer MRC-5 cells in the amount of 100 μl / well, and 4 duplicate wells were set for each concentration, and cultured After 2 hours, inoculate 100 μl / well of 100TCID50 (virus infectivity titer) HSV-1 virus liquid, and place in a 5% CO2 cell incubator to continue culturing for 2 hours. After the virus is completely a...

Embodiment 2

[0034] The dilution method of the 1,2,3,4,6-penta-O-galloyl-b-D-glucose drug and the positive control drug ACV is the same as in Example 1.

[0035] First inoculate 100 TCID50 of HSV-1 on the monolayer of MRC-5 cells in a 24-well plate, adsorb for 2 hours in a CO2 cell incubator at 37°C, and then add 20 μg / ml, 10 μg / ml, 5 μg / ml, 2.5 μg / ml , 1.25 μg / ml of 1,2,3,4,6-penta-O-galloyl-b-D-glucose maintenance solution and 20 μg / ml, 10 μg / ml, 5 μg / ml, 2.5 μg / ml, 1.25 μg / ml Add ACV maintenance solution to the wells of monolayer MRC-5 cells at the amount of 100 μl / well, set 4 duplicate wells for each concentration, and place in 5% CO 2 Continue culturing in the cell culture box for 72 hours, and observe the formation of plaques. At the same time, a virus control group and a normal cell control group were set up, and the experiment was repeated 3 times.

[0036]Test analysis method:

[0037] Count the number of plaques formed under different drug concentrations, and calculate IC50. ...

Embodiment 3

[0040] The dilution method of the 1,2,3,4,6-penta-O-galloyl-b-D-glucose drug and the positive control drug ACV is the same as in Example 1.

[0041] 20μg / ml, 10μg / ml, 5μg / ml, 2.5μg / ml, 1.25μg / ml of 1,2,3,4,6-penta-O-galloyl-b-D-glucose maintenance solution and HSV-1 After mixing 100 μl of each storage solution, add 200 μl / well to the single-layer MRC-5 cells in a 24-well plate, set 4 duplicate wells for each concentration, and culture in a 5% CO2 cell incubator for 72 hours, observe the drug Comprehensive effects on HSV-1-infected cells. At the same time, a virus control group and a normal cell control group were set up, and the experiment was repeated 3 times.

[0042] Test analysis method:

[0043] The number of plaques formed under the action of each drug concentration was counted, and the IC50 was calculated.

[0044] The results showed that the half effective dose (IC50) of 1,2,3,4,6-penta-O-galloyl-b-D-glucose to prevent HSV-1 infection was 5.340 μg / ml. It can be see...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of 1,2,3,4,6-penta-O-galloyl-b-D-glucose in preparing a medicine for resisting herpes simplex viruses, and in particular relates to application of the 1,2,3,4,6-penta-O-galloyl-b-D-glucose in preparing a medicine for resisting herpes simplex virus type 1. The 1,2,3,4,6-penta-O-galloyl-b-D-glucose has the function of preventing and treating cells infected by HSV-1, can also reduce the infectivity of the HSV-1 on MRC-5 cells, has the function of directly killing the HSV-1, and can reduce the activity of MRC-5 cells infected by the HSV-1; and the medicine for resisting the herpes simplex virus type 1 prepared by taking the 1,2,3,4,6-penta-O-galloyl-b-D-glucose as an effective ingredient has high suppression ratio on the herpes simplex virus type 1 within a safe dosage range, has strong function of preventing infection of the herpes simplex virus type 1, quickly cures patients, can relieve syndromes of infected patients, and has low toxicity and good stability.

Description

technical field [0001] The present invention relates to the use of 1,2,3,4,6-penta-O-galloyl-b-D-glucose as a medicine for preparing anti-herpes simplex virus, in particular to its use as a medicine for preparing anti-herpes simplex virus type 1, belongs to the field of pharmaceuticals. Background technique [0002] 1,2,3,4,6-penta-O-galloyl-b-D-glucose is extracted from the branches and leaves of emblica (phyllanthus emblica L.). Phyllanthus emblica L. comes from the mature fruit of Euphorbiaceae (Phyllanthus), also known as Yunnan olive and oil orange, and is widely distributed in West Asia, North Africa, southern India and Southeast Asia. It is distributed in the southwest to southeast coastal areas of my country. It has a very long history of medication in my country's Chinese herbal medicine, Tibetan medicine, Mongolian medicine, Dai medicine, Uighur medicine and other ethnic medicine systems, as well as in India's Vedic traditional medicine system. [0003] Herpes s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7024A61P31/12
Inventor 王一飞张颖君杨崇仁裴赢钱垂文张美英刘青北里海雄
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com